Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Clinical Trial

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795343

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795343

Sarcoidosis Therapeutics

PUBLISHED:
PAGES: 175 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Sarcoidosis Therapeutics Market to Reach US$385.0 Million by 2030

The global market for Sarcoidosis Therapeutics estimated at US$302.4 Million in the year 2024, is expected to reach US$385.0 Million by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Corticosteroids Therapeutics, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$227.3 Million by the end of the analysis period. Growth in the Other Therapeutics Types segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$79.5 Million While China is Forecast to Grow at 4.1% CAGR

The Sarcoidosis Therapeutics market in the U.S. is estimated at US$79.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$62.4 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Sarcoidosis Therapeutics Market - Key Trends & Drivers Summarized

What Is Fueling the Advancements in the Therapeutic Landscape for Sarcoidosis?

Sarcoidosis, a complex multisystem inflammatory disease of unknown etiology, has seen incremental yet meaningful advancements in therapeutic options over the past decade. Characterized by non-caseating granulomas that predominantly affect the lungs, lymph nodes, skin, and eyes, sarcoidosis remains challenging to treat due to its heterogeneity, variable progression, and poorly understood pathophysiology. Glucocorticoids such as prednisone have long served as first-line treatments due to their anti-inflammatory efficacy. However, the adverse effects associated with prolonged corticosteroid use-including osteoporosis, hyperglycemia, and weight gain-have led to growing interest in corticosteroid-sparing strategies.

Second-line immunosuppressive agents such as methotrexate, azathioprine, and leflunomide have gained traction for chronic and corticosteroid-refractory cases. More recently, biological agents targeting specific immune pathways have emerged as promising therapeutic avenues. Tumor necrosis factor-alpha (TNF-α) inhibitors such as infliximab and adalimumab have shown efficacy in refractory sarcoidosis, especially in extrapulmonary manifestations including neurosarcoidosis and cutaneous sarcoidosis. The expansion of evidence-based guidelines, growing clinical trial data, and increasing awareness among specialists are reshaping treatment protocols and encouraging a more individualized, stepwise approach to managing sarcoidosis.

How Are Emerging Therapies and Targeted Interventions Reshaping Disease Management?

The future of sarcoidosis therapeutics lies in the development of targeted therapies that modulate specific components of the immune response without compromising overall immune function. Recent clinical trials are exploring agents that interfere with granuloma formation, T-cell signaling, and fibrotic pathways. Janus kinase (JAK) inhibitors, such as tofacitinib and ruxolitinib, are under investigation for their ability to suppress pro-inflammatory cytokines and halt disease progression in steroid-resistant sarcoidosis. Interleukin-targeted therapies, including IL-6 and IL-12/23 inhibitors, are also being studied for potential efficacy in reducing systemic inflammation with a more favorable safety profile.

Antifibrotic agents like nintedanib and pirfenidone-originally approved for idiopathic pulmonary fibrosis-are being evaluated for their utility in pulmonary sarcoidosis cases with progressive fibrosis. These candidates represent a shift in therapeutic thinking from inflammation suppression to structural lung preservation. Meanwhile, advances in molecular profiling and biomarker discovery are enabling clinicians to better stratify patients based on disease phenotype and treatment response. This precision medicine approach is expected to reduce trial-and-error prescribing and improve long-term outcomes. Drug repurposing strategies are also gaining momentum, with existing immunomodulators being reassessed for sarcoidosis via adaptive clinical trial designs and real-world evidence databases.

Which Patient Populations and Regional Trends Are Influencing Market Expansion?

Sarcoidosis exhibits notable geographic, racial, and demographic variability, which in turn influences market demand and treatment practices. The disease has higher prevalence among African American populations, particularly women aged 20-40, who often experience more severe and chronic forms of sarcoidosis. Scandinavia, Germany, and Japan report distinct incidence clusters, with more cases involving cardiac and ocular manifestations. In the United States, recent healthcare reforms and digital health initiatives have improved access to specialist care, allowing for earlier diagnosis and intervention. However, disparities remain in underinsured and rural populations, where sarcoidosis often goes underdiagnosed or mismanaged.

In Europe, collaborative research networks and centralized registries are enabling standardized disease characterization and fostering multicenter trials. Germany, the Netherlands, and the UK are leading contributors to clinical research in this area. Japan is witnessing a rise in ocular sarcoidosis cases, prompting more ophthalmologist-led therapeutic interventions. In low- and middle-income countries, awareness and diagnosis remain low due to limited access to advanced imaging and biopsy facilities. However, as diagnostic capabilities improve and telemedicine expands, emerging markets are expected to contribute increasingly to the global demand for sarcoidosis therapies, especially for oral immunosuppressants and cost-effective biologics.

What Are the Key Drivers Accelerating Growth in the Sarcoidosis Therapeutics Market?

The growth in the sarcoidosis therapeutics market is driven by several interlinked factors, including unmet clinical needs, the emergence of biologics and small molecules, and improved diagnostic protocols. Traditional corticosteroid-based management, while effective in the short term, carries substantial long-term risk, creating a clinical imperative for safer, targeted alternatives. The increasing burden of chronic sarcoidosis, particularly in pulmonary and cardiac forms, is propelling demand for advanced therapeutics that minimize systemic toxicity and preserve organ function. Rising awareness among clinicians, coupled with the proliferation of disease-specific treatment algorithms, is encouraging more aggressive and tailored intervention strategies.

Pharmaceutical innovation and strategic investments in rare inflammatory disease research are expanding the therapeutic pipeline, with multiple Phase II and III trials underway across North America and Europe. Regulatory agencies are offering orphan drug designations, fast-track approvals, and research grants to incentivize innovation in this neglected space. Real-world evidence platforms and patient registries are providing insights into disease progression, treatment effectiveness, and healthcare utilization, helping guide market expansion. Moreover, cross-disciplinary collaboration among pulmonologists, rheumatologists, dermatologists, and neurologists is fostering a more holistic view of sarcoidosis care, paving the way for integrated treatment models and expanded therapeutic uptake across diverse healthcare systems.

SCOPE OF STUDY:

The report analyzes the Sarcoidosis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Corticosteroids Therapeutics, Other Therapeutics Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Adaptimmune Therapeutics Plc
  • Amgen Inc.
  • aTyr Pharma Inc.
  • Bellus Health Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Foresee Pharmaceuticals Co. Ltd.
  • GSK plc
  • Hikma Pharmaceuticals PLC
  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • Kinevant Sciences GmbH
  • Kyorin Pharmaceutical Co., Ltd.
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Molecure S.A.
  • Novartis AG
  • Pfizer Inc.
  • Relief Therapeutics Holding SA
  • Xentria Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37967

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Sarcoidosis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Granulomatous Diseases Throws the Spotlight on Sarcoidosis Therapeutics
    • Increased Awareness and Early Diagnosis Spur Demand for First-Line Anti-Inflammatory Treatments
    • Expansion of Multisystemic Disease Understanding Strengthens Business Case for Multimodal Therapy
    • Advances in Immunomodulatory Agents Propel Development of Targeted Sarcoidosis Therapies
    • Growing Use of Biologics in Refractory Sarcoidosis Accelerates Pipeline Innovation
    • Development of Corticosteroid-Sparing Strategies Generates Demand for Novel Mechanisms of Action
    • Increased Application of Personalized Medicine Approaches Expands Therapeutic Customization
    • Collaborative Research Initiatives With Rare Disease Networks Fuel Clinical Data Generation
    • Expansion of Real-World Evidence Databases Strengthens Market Access and Reimbursement Justifications
    • Growing Recognition of Cardiac and Neurosarcoidosis as Distinct Subtypes Expands Therapeutic Scope
    • Regulatory Support for Orphan Drug Designations Accelerates Development Timelines
    • Integration of Digital Biomarkers and Imaging Tools Enhances Monitoring of Disease Progression
    • Rising Participation in Multinational Clinical Trials Boosts Global Product Development Pipelines
    • Demand for Multidisciplinary Treatment Approaches Drives Cross-Specialty Therapeutic Strategies
    • Increased Focus on Patient-Reported Outcomes and Quality of Life Metrics Supports Value-Based Pricing
    • Availability of Compassionate Use Programs Enhances Market Entry for Investigational Products
    • Partnerships Between Pharma and Academia Strengthen Translational Research in Autoimmune Diseases
    • Expansion of Health Policy Support in Rare and Underdiagnosed Diseases Propels Market Recognition
    • Growth in Biopharmaceutical Investment in Inflammatory and Fibrotic Pathways Fuels Sarcoidosis R&D
    • Advances in Pulmonary and Systemic Sarcoidosis Classification Enhance Therapeutic Targeting
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sarcoidosis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sarcoidosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Sarcoidosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroids Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Corticosteroids Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Corticosteroids Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Therapeutics Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Other Therapeutics Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Other Therapeutics Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Sarcoidosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Sarcoidosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!